ACAD
Acadia Pharmaceuticals Inc
$26.20
+0.43 (+1.67%)
At close · Jul 7
Market Cap
$4.49B
Shares
171,235,870
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.07B
+11.9%
FY2025
Net Income
$391M
+72.7%
FY2025
Gross Margin
94.27%
-3.8pp
FY2023
Operating Margin
9.78%
-14.3pp
FY2025
Diluted EPS
$2.30
+69.1%
FY2025
Operating Cash Flow
$109.84M
-30.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.1B | $1.07B | $957.8M | $726.44M | $517.24M | $484.15M | $441.76M | $339.08M | $223.81M | $124.9M | $17.33M | $61K | $120K | $1.15M | $4.91M | $2.07M | $42.14M | $6.4M | |
| $93.4M | $89M | $81.84M | $41.64M | $10.17M | $19.14M | $10.21M | $11.34M | $12.38M | $9.08M | $3.08M | — | — | — | — | — | — | — | |
| — | — | — | $684.8M | $507.07M | $473.3M | $431.54M | $327.73M | $211.43M | $115.82M | $14.25M | — | — | — | — | — | — | — | |
| — | — | — | 94.27% | 98.03% | 97.76% | 97.69% | 96.65% | 94.47% | 92.73% | 82.23% | — | — | — | — | — | — | — | |
| $327.41M | $328.8M | $303.25M | $351.62M | $361.58M | $239.42M | $319.13M | $240.39M | $187.16M | $149.19M | $99.28M | $73.87M | $60.6M | $26.72M | $18.79M | $17.31M | $20.58M | $41.59M | |
| $91.53M | — | — | — | — | — | — | — | — | — | — | $88.3M | $32.75M | $12.72M | $7M | $7.61M | $6.46M | $10.28M | |
| $593.54M | $548.89M | $488.43M | $406.56M | $369.09M | $396.03M | $388.66M | $325.64M | $265.76M | $255.06M | $186.46M | $88.3M | $32.75M | — | — | — | — | — | |
| — | $10.89M | $14.96M | $4.09M | $0 | $1.11M | $1.48M | $1.48M | $1.48M | $1.48M | $985K | $0 | $0 | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $206K | $79K | $109K | $285K | — | — | |
| $174.38M | — | — | — | — | — | — | — | — | — | — | $164.67M | $93.35M | $39.44M | $25.79M | $24.92M | $27.04M | $51.87M | |
| $1.01B | $966.69M | $727M | $799.82M | $740.83M | $654.58M | $728.34M | $585.62M | $471.25M | $417.31M | $290.15M | $164.67M | $93.35M | — | — | — | — | — | |
| $80.91M | $104.81M | $230.79M | -$73.38M | -$223.6M | -$170.44M | -$286.59M | -$246.55M | -$247.44M | -$292.41M | -$272.82M | -$164.61M | -$93.23M | -$38.3M | -$20.89M | -$22.85M | $15.09M | -$45.47M | |
| — | 9.78% | 24.1% | -10.1% | -43.23% | -35.2% | -64.87% | -72.71% | -110.56% | -234.11% | -1574.14% | -269855.74% | -77691.67% | -3344.72% | -425.64% | -1105.56% | 35.82% | -710.55% | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$93.02M | -$38.22M | -$20.78M | -$22.57M | — | — | |
| $2.33M | $2.37M | $1.82M | $5.11M | $3.54M | $2.33M | -$997K | $997K | -$1.84M | — | — | — | — | — | — | — | — | — | |
| — | $138.9M | $258.08M | -$51.04M | -$213.44M | -$167.52M | -$280.97M | -$234.38M | — | — | — | — | — | — | — | — | — | — | |
| — | $0 | $0 | $5.11M | $3.54M | $2.33M | -$997K | $997K | -$1.84M | — | — | — | — | — | — | — | — | — | |
| $115.11M | $138.9M | $258.08M | -$51.04M | -$213.44M | -$167.52M | -$280.97M | -$234.38M | -$243.94M | -$288.28M | -$270.05M | -$164.11M | -$92.48M | -$37.95M | — | — | — | — | |
| -$260.54M | -$252.1M | $31.62M | $10.25M | $2.53M | $351K | $611K | $876K | $1.26M | $1.12M | $1.34M | $330K | $0 | $0 | $0 | $17K | $12K | — | |
| $375.65M | $391M | $226.45M | -$61.29M | -$215.98M | -$167.87M | -$281.58M | -$235.26M | -$245.19M | -$289.4M | -$271.39M | -$164.44M | -$92.48M | -$37.95M | -$20.85M | -$22.77M | $15.14M | -$45.15M | |
| — | 36.49% | 23.64% | -8.44% | -41.76% | -34.67% | -63.74% | -69.38% | -109.56% | -231.71% | -1565.94% | -269578.69% | -77062.5% | -3314.24% | -424.88% | -1101.35% | 35.93% | -705.5% | |
| $375.65M | $391M | $226.45M | -$61.29M | -$215.98M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $374.65M | $392.15M | $226.72M | -$60.29M | -$216.76M | -$168.1M | -$281.85M | -$234.59M | -$245.17M | -$289.91M | -$271.3M | -$164.42M | -$92.53M | -$37.9M | -$20.85M | -$23.27M | $15.17M | — | |
| USD/shares | — | $2.32 | $1.37 | -$0.37 | -$1.34 | -$1.05 | -$1.79 | — | — | — | — | — | — | — | -$0.38 | -$0.44 | $0.39 | -$1.20 |
| USD/shares | — | $2.30 | $1.36 | -$0.37 | -$1.34 | -$1.05 | -$1.79 | — | — | — | — | — | — | — | -$0.38 | -$0.44 | $0.39 | -$1.20 |
| shares | — | 168.36M | 165.72M | 163.82M | 161.68M | 160.49K | 157.33K | 147.2M | 126.58M | 122.6M | 115.86M | 100.63M | 97.25M | 85.72M | 55.12M | 52.18M | 38.59M | 37.48M |
| shares | — | 169.92M | 166.36M | 163.82M | 161.68M | 160.49K | 157.33K | 147.2M | 126.58M | 122.6M | 115.86M | 100.63M | 97.25M | 85.72M | 55.12M | 52.18M | 38.72M | 37.48M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
11.86×
Biotechnology median 7.60×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Reportable Segment Aggregation Before Other Operating Segment | $1,071,505,000 | $957,797,000 | $726,437,000 | $517,235,000 |
Key facts
CIK
1070494
CUSIP
004225108
13F (30d)
11 filings
10 filers
Visit website
Investor relations